Lund, Sweden | 16 June 2025 | Nygen Analytics, the only single‑cell–focused omics data‑analytics platform to pair ISO 27001 certification with SOC 2 attestation while maintaining full GDPR alignment, today announced the successful completion of both independent audits. The combined compliance stack eradicates a major regulatory hurdle for biopharma and biotech organisations, enabling scientists to advance drug‑discovery programs with confidence that their research data meet the world’s most stringent security and privacy standards.
“For biopharma innovators, every extra week spent validating a vendor’s security controls is a week not spent moving a therapeutic candidate closer to patients,” said Parashar Dhapola, PhD, Chief Executive Officer at Nygen Analytics. “By internalising the stringent requirements of ISO 27001, SOC 2 and GDPR, Nygen removes that overhead so our partners can focus on unlocking the biological insights that will power the next generation of medicines.”
ISO/IEC 27001 certifies that Nygen’s information‑security management system adheres to the international benchmark for risk management, business continuity and operational resilience, while the SOC 2 attestation affirms that Nygen’s controls for security, availability, processing integrity, confidentiality and privacy have been rigorously audited over time. Stakeholders can review real‑time compliance badges, audit summaries and control narratives in Nygen’s public Trust Center at trust.nygen.io.
Beyond its role as an enabling analytics platform, Nygen hosts a curated, GDPR‑compliant repository of harmonised single‑cell multi‑omics datasets that biopharma and biotech teams can leverage to de‑risk early‑stage discovery pipelines and accelerate target validation.
Nygen Analytics delivers an intuitive, cloud‑native platform that democratises single‑cell multi‑omics analysis and interpretation for bench scientists and bioinformaticians in biopharma and biotech. Its integrated product suite, Nygen Analytics, Nygen Database and Nygen Insights combines scalable computation, reproducible pipelines and AI‑driven discovery tools to accelerate therapeutics development in early stage drug discovery pipelines.
Media Contact
sukhitha@nygen.io
